The question of whether young age is an independent prognostic factor in breast cancer has divided researchers for decades. Breast cancer remains the fourth leading cause of cancer-related death worldwide, and young age at diagnosis has repeatedly been linked to higher recurrence rates and shorter disease-free survival. Skeptics have argued that the apparent disadvantage simply reflects confounding: young patients tend to present with more aggressive tumor biology, including high-grade disease, lymphovascular invasion, elevated proliferation, and an enrichment of hormone receptor-negative, HER2-positive, and basal-like tumors. They are also more frequently diagnosed at advanced stages. Yet several large analyses have found that young age persists as a risk factor even after adjustment for stage and receptor status, and patients under 35 show increased risks of recurrence and distant metastasis that pathological features alone cannot explain.

To dissect this puzzle, the study drew on the TCGA PanCancer Atlas Breast Invasive Carcinoma cohort accessed through cBioPortal. After a careful filtering process that excluded stage IV disease, unknown stages, and tumors with Normal-like or missing PAM50 classifications, the final analytical cohort comprised 821 patients with invasive ductal or invasive lobular carcinoma: 142 aged 45 years or younger and 679 older than 45. The cutoff of 45 years was chosen to align with previous genomic studies, and sensitivity analyses using thresholds of 35, 40, and 50 years were performed to guard against the arbitrariness of any single definition of “young.”

The clinicopathological comparison revealed that young patients were significantly more likely to have invasive ductal carcinoma, at 94.4 percent versus 79.4 percent in older patients, and more likely to have lymph node involvement, with only 38 percent showing node-negative disease compared with 51.2 percent of older patients. Notably, however, estrogen receptor, progesterone receptor, HER2 status, intrinsic subtype, tumor size, and overall stage distribution did not differ significantly between the groups. Survival analyses then showed that young patients had significantly worse disease-free survival, with a log-rank p-value of 0.001, while overall survival and disease-specific survival did not differ significantly. The absolute burden of recurrence was striking: five-year disease-free survival event rates were 23.1 percent in young patients versus 10.8 percent in older patients, widening to 35.7 percent versus 13.8 percent at ten years. Restricted mean survival time analysis quantified a loss of 2.9 months within five years and 13.9 months within ten years for young patients, indicating that the prognostic gap widened over time.

The core of the study lay in constructing the molecular signature. Differential expression analysis between age groups identified 614 age-associated genes at a false discovery rate below 0.1, while univariable Cox regression flagged 529 genes linked to disease-free survival at a p-value below 0.01. Intersecting these sets yielded 11 candidates, which were then subjected to LASSO-Cox regression with 10-fold cross-validation, followed by stepwise multivariable selection based on the Akaike information criterion. The result was a parsimonious four-gene model comprising C4orf14, also known as NOA1, LINC01124, ZNF704, and AGFG2. Each patient’s Sig4 score was calculated as a weighted linear combination of the log2-transformed expression values of these genes, with fixed regression coefficients derived from the TCGA cohort.

The statistical performance of Sig4 was the study’s most provocative finding. In univariable analysis, young age carried a hazard ratio of 2.44 for poor disease-free survival, and this association remained significant after adjustment for stage and intrinsic subtype. But when the continuous Sig4 score was added to the fully adjusted model, Sig4 itself emerged as a strong independent predictor, with a hazard ratio of 2.18 per one-standard-deviation increase, while the coefficient for young age attenuated to a statistically non-significant 1.43. The author is careful to note that this attenuation indicates overlapping prognostic information between age and the signature, but does not prove that Sig4 mediates or causally explains the age effect. Within the young subgroup alone, Sig4 remained independently associated with disease-free survival, a result reinforced by bootstrap resampling with 1000 iterations, and descriptive Kaplan-Meier curves showed significantly poorer survival among young patients with high Sig4 scores.

Biological context came from gene set enrichment analysis. Tumors with high Sig4 scores were enriched for proliferation- and cell cycle-related pathways, including MYC targets, E2F targets, the G2-M checkpoint, and mitotic spindle assembly, along with DNA repair, mTORC1 signaling, glycolysis, oxidative phosphorylation, and the unfolded protein response. In contrast, Sig4-low tumors showed relative enrichment of early and late estrogen response pathways. Single-sample enrichment analysis confirmed these differences at the individual tumor level. The four component genes themselves span diverse functions: NOA1 is a mitochondrial GTPase involved in mitoribosome biogenesis and respiration; LINC01124 is a long noncoding RNA implicated in proliferation and invasion; ZNF704 is a zinc finger repressor linked to circadian disruption and metastasis in breast cancer; and AGFG2 participates in vesicular trafficking, potentially reflecting tumor-microenvironment interactions.

External validation in the independent METABRIC cohort of 1134 matched cases provided partial support. Using the fixed TCGA-derived coefficients, the Sig4 score was significantly associated with worse relapse-free survival both as a continuous variable and when dichotomized at the cohort median, and Sig4-high status remained significant in multivariable models, in stratified Cox analyses, and in models incorporating a time-varying coefficient for young age. However, the validation was not uniformly successful: when the analysis was restricted to young METABRIC patients aged 45 or younger, the Sig4 score showed no significant association with relapse-free survival. The author attributes this to possible differences in cohort composition, treatment background, expression platform, endpoint definitions, and statistical precision, and concludes that the signature’s utility specifically for young-onset disease remains unproven.

The study is candid about its limitations. It is a retrospective analysis of public datasets with incomplete treatment and hereditary predisposition information, meaning that chemotherapy, endocrine therapy, HER2-targeted treatment, and germline BRCA status could all have influenced the observed associations. The limited number of disease-free survival events relative to the number of genes screened raises the specter of overfitting, despite the penalized regression approach, and the bulk RNA sequencing data cannot separate tumor-intrinsic programs from microenvironmental contributions. The author therefore positions Sig4 as an exploratory candidate signature rather than a clinically applicable biomarker, emphasizing that translation into practice would require analytical standardization, prospective validation, and evidence that the score improves decisions beyond existing clinicopathological and molecular tools. Even so, the work offers a compelling demonstration that the transcriptomic landscape of young-onset breast cancer carries prognostic weight, and it points toward a future in which age-associated molecular signatures could help identify which young patients truly need intensified surveillance and therapy.

Subject of Research: An age-associated four-gene prognostic signature for recurrence risk in breast cancer

Article Title: Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer

Article References: Uchida, S. (2026). Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer. Cancer Reports, 9(9), Article e70670. https://doi.org/10.1002/cnr2.70670

Image Credits: AI Generated

DOI: 10.1002/cnr2.70670

Keywords: breast cancer, prognostic signature, young-onset breast cancer, gene expression, TCGA, METABRIC, disease-free survival, LASSO-Cox regression, molecular biomarker, recurrence risk, transcriptomics, Cancer Reports